Vetter Pharma

OverviewSuggest Edit

Vetter Pharma is a company specializing in the aseptic filling of syringes, cartridges, vials, and dual-chamber systems, as well as packaging and device assembly solutions. It provides process development, clinical trial manufacturing, analytical, technology transfer, life cycle management, and other services.
TypePrivate
Founded1950
HQRavensburg, DE
Websitevetter-pharma.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Mar 2021)5,500(+10%)
Revenue (FY, 2018)€594.9 M(+6%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Vetter Pharma

Thomas Otto

Thomas Otto

Managing Director
Peter Soelkner

Peter Soelkner

Managing Director
Carsten Press

Carsten Press

Senior Vice President Key Account Management, SCM, Marketing
Bernd Stauß

Bernd Stauß

Senior Vice President Production / Engineering
Andrea Wesp

Andrea Wesp

Vice President New Business
Jörg Zimmermann

Jörg Zimmermann

Vice President External Affairs
Show more

Vetter Pharma Office Locations

Vetter Pharma has offices in Ravensburg, Langenargen, Des Plaines, Skokie and in 5 other locations
Ravensburg, DE (HQ)
Schützenstraße 87
Langenargen, DE
Eisenbahnstraße 2-4
Ravensburg, DE
Eywiesenstraße 5
Ravensburg, DE
Helmut-Vetter-Straße 10
Ravensburg, DE
Im Wiesental 7
Ravensburg, DE
Mooswiesen 2
Show all (13)

Vetter Pharma Financials and Metrics

Summary Metrics

Founding Date

1950
Show all financial metrics

Vetter Pharma Revenue

Vetter Pharma's revenue was reported to be €594.95 m in FY, 2018 which is a 5.9% increase from the previous period.
EUR

Revenue (FY, 2018)

594.9m

Revenue growth (FY, 2017 - FY, 2018), %

5.9%

Cash (31-Dec-2018)

3.9m
EURFY, 2016FY, 2017FY, 2018

Revenue

503.2m562.1m594.9m

Revenue growth, %

12%6%

General and administrative expense

228.5m253.2m265.6m

Operating expense total

228.5m253.2m265.6m
EURFY, 2016FY, 2017FY, 2018

Cash

9.0m1.7m3.9m

Accounts Receivable

90.8m107.4m107.8m

Prepaid Expenses

1.8m2.4m2.7m

Inventories

85.1m81.6m91.1m
EURFY, 2016

Revenue/Employee

134.9k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.3 x
Show all financial metrics

Vetter Pharma Operating Metrics

FY, 2016FY, 2017FY, 2018

New Drugs Approved (EU)

2845

New Drugs Approved (Germany)

3136

New Drugs Approved (USA)

224659

Vetter Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Arzneimittel GmbH Apotheker Vetter & Co. KG
Vetter Commercial Manufacturing USA
Vetter Development Services USA, Inc
Vetter Pharma International GmbH
Vetter Pharma International Japan KK
Vetter Pharma International USA Inc

Vetter Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Vetter Pharma Online and Social Media Presence

Embed Graph

Vetter Pharma News and Updates

Vetter’s New Clinical Manufacturing Site Now Fully Integrated

A growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners that provide strategic support and comprehensive resources for their development process of new, promising injectable drug products. Vetter, a leading global Contract Development and Manufacturing Or…

Vetter establishes office in China to better serve the needs of its growing customer base worldwide

Vetter, one of the global leaders in prefilled drug-delivery systems, today announced the opening of a new business entity in Shanghai, China. The new office, now its fourth in the Asia Pacific (APAC) region, will help increase the visibility of Vetter’s presence in China and underlines its importan…

Vetter continues its long-term investment strategy to sustain future growth

Vetter, a globally leading contract development and manufacturing organization (CDMO), has moved into its new headquarters in Ravensburg, Germany. The opening of the new building, known as Ravensburg Vetter Kammerbruehl, represents a clear signal from the family-owned company: stability and progress…

Teaming up to tackle drug development complexity

Vetter and Rentschler Biopharma are collaboratively developing a best-in-breed approach that reduces time-to-market. With global demand surging, biopharma companies are under significant pressure to accelerate new products to the clinic and market. At the same time, both the cost and complexity of d…

Increasing regulatory requirements demand innovative production methods

Ute Schleyer spoke with Outsourcing-Pharma about the factors driving demand for aseptic solutions, including V-CRT®. Demand for specialized treatments and therapies continues to surge around the world. At the same time, global health authorities are placing increasingly stringent demands on the asep…

Vetter opens new Training Center

On September 14, the Vetter Training Center site opened its doors – with a small celebration and a good atmosphere. The building, which has been specially converted for trainees and students, houses various workshops where they build their technical skills. They will also learn about innovative meth…
Show more

Vetter Pharma Frequently Asked Questions

  • When was Vetter Pharma founded?

    Vetter Pharma was founded in 1950.

  • Who are Vetter Pharma key executives?

    Vetter Pharma's key executives are Thomas Otto, Peter Soelkner and Carsten Press.

  • How many employees does Vetter Pharma have?

    Vetter Pharma has 5,500 employees.

  • What is Vetter Pharma revenue?

    Latest Vetter Pharma annual revenue is €594.9 m.

  • What is Vetter Pharma revenue per employee?

    Latest Vetter Pharma revenue per employee is €108.2 k.

  • Who are Vetter Pharma competitors?

    Competitors of Vetter Pharma include B. Braun Melsungen, B. Braun and KBI Biopharma.

  • Where is Vetter Pharma headquarters?

    Vetter Pharma headquarters is located at Schützenstraße 87, Ravensburg.

  • Where are Vetter Pharma offices?

    Vetter Pharma has offices in Ravensburg, Langenargen, Des Plaines, Skokie and in 5 other locations.

  • How many offices does Vetter Pharma have?

    Vetter Pharma has 13 offices.